[
  {
    "ts": null,
    "headline": "Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth",
    "summary": "Guardant Health (NasdaqGS:GH) agreed to acquire MetaSight Diagnostics, expanding its liquid biopsy capabilities into early cancer and liver fibrosis detection. The company is growing the reach of its Shield colorectal cancer screening test through new partnerships with Quest Diagnostics and PathGroup. Recent updates also include strong revenue growth and new product launches, adding to the company’s broader oncology diagnostics offering. Guardant Health focuses on blood based tests for...",
    "url": "https://finnhub.io/api/news?id=216a1fded5aad5fc4b5275524e26b80bd4e7aa11b6b40435d9d27dd42b825b10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771855642,
      "headline": "Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth",
      "id": 139185426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Guardant Health (NasdaqGS:GH) agreed to acquire MetaSight Diagnostics, expanding its liquid biopsy capabilities into early cancer and liver fibrosis detection. The company is growing the reach of its Shield colorectal cancer screening test through new partnerships with Quest Diagnostics and PathGroup. Recent updates also include strong revenue growth and new product launches, adding to the company’s broader oncology diagnostics offering. Guardant Health focuses on blood based tests for...",
      "url": "https://finnhub.io/api/news?id=216a1fded5aad5fc4b5275524e26b80bd4e7aa11b6b40435d9d27dd42b825b10"
    }
  }
]